MediWound Ltd. (MDWD) - Form 20-F Summary
Business Context and Reporting Period
Company: MediWound Ltd.
Reporting Period: Fiscal year ended December 31, 2016
Jurisdiction: Israel (Foreign Private Issuer)
Accounting Standard: International Financial Reporting Standards (IFRS)
Business Overview: MediWound is a biopharmaceutical company developing and commercializing products based on patented proteolytic enzyme technology. Its primary commercial product is NexoBrid, approved in the EU, Israel, and Argentina for the non-surgical debridement of severe burns. The company is also developing EscharEx for chronic wounds and pipeline candidates for connective tissue disorders.
Key Financial Metrics (Year Ended Dec 31, 2016)
| Metric | 2016 (in thousands) | 2015 (in thousands) |
|---|---|---|
| Revenues | $1,558 | $601 |
| Cost of Revenues | $2,158 | $2,519 |
| Gross Loss | $(600) | $(1,918) |
| Operating Loss | $(20,155) | $(21,227) |
| Net Loss | $(18,885) | $(22,088) |
| Net Loss Per Share (Basic/Diluted) | $(0.86) | $(1.02) |
| Cash and Cash Equivalents | $30,029 | $45,768 |
| Working Capital (Net) | $28,232 | $45,189 |
| Total Shareholders' Equity | $7,770 | $23,470 |
Note: The company reported a net loss of $18.9 million for 2016, an improvement from $22.1 million in 2015. Revenues grew 159% year-over-year, driven by NexoBrid sales in Europe, Israel, and Argentina.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased from $0.6 million in 2015 to $1.6 million in 2016, reflecting expanded commercialization of NexoBrid.
- Cost of Revenues: Decreased 14% to $2.2 million, despite revenue growth, due to an increased allotment of manufacturing costs to R&D expenses (specifically for EscharEx development).
- R&D Expenses: Gross R&D expenses surged 82% to $14.8 million, driven by the U.S. Phase 3 pivotal study for NexoBrid and development of EscharEx. However, net R&D expenses (after government grants) increased only 17% to $7.1 million due to significant funding from BARDA ($5.6 million) and the Israeli Innovation Authority ($2.1 million).
- Liquidity: Cash and cash equivalents decreased by approximately $15.7 million to $30.0 million, primarily due to operating cash outflows and reduced proceeds from short-term bank deposits compared to 2015.
- Financial Income: Increased to $2.2 million (from $1.1 million in 2015), largely due to the revaluation of contingent consideration for the purchase of shares.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- The company expects to continue incurring significant operating losses for the foreseeable future as it advances clinical trials and expands commercial operations.
- Management anticipates that existing cash reserves ($30 million) will be sufficient to fund operations for the next 12 months.
- Key milestones include the completion of the U.S. Phase 3 pivotal study (DETECT) for NexoBrid, with top-line results expected in the first half of 2018, and the ongoing pediatric study in Europe.
- The company plans to construct a new manufacturing facility, estimated to cost $10-15 million, with qualification expected in 2020.
- Regulatory Approval: Success depends heavily on obtaining FDA approval for NexoBrid in the U.S. Failure to receive approval would materially impact business prospects.
- Government Funding Dependency: The company relies on a contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $112 million. BARDA may terminate the contract at any time without further funding obligations.
- Legal Proceedings: Ongoing litigation with PolyHeal Ltd. shareholders regarding a potential obligation to purchase shares (approx. $1.5 million) and disputes with Teva Pharmaceutical Industries regarding payments totaling $4.7 million.
- Supply Chain: Dependence on a single supplier (Challenge Bioproducts Corporation) for the intermediate drug substance (bromelain SP).
- Geopolitical Risk: Operations are based in Israel, exposing the company to risks related to regional instability, military service obligations of employees, and potential boycotts.
Investor Verification Checklist
- BARDA Contract Status: Verify the current status of the BARDA contract and any potential for termination or reduction in funding, as this significantly offsets R&D costs.
- U.S. Phase 3 Trial Progress: Monitor enrollment rates and interim data for the DETECT study, which is critical for FDA approval.
- Liquidity Runway: Confirm that the $30 million cash balance remains sufficient given the high burn rate and planned capital expenditures for the new manufacturing facility.
- Legal Exposure: Review updates on the PolyHeal and Teva litigation to assess potential cash outflows or liabilities.
- Reimbursement Status: Track progress of reimbursement approvals in key European markets (e.g., Belgium, Italy) and potential expansion into other territories.